News round-up for 2-6 September by DDW Senior Digital Content Editor Diana Spencer.

With the release of clinical study results that led some media titles to ask if semaglutide could be a ‘fountain of youth’, this week our news highlights focus on clinical trials at a variety of different stages.

The top stories:

Colorectal cancer study to be discontinued

NuCana has revealed that the NuTide:323 colorectal cancer study is being discontinued following a pre-planned initial analysis and recommendation from the NuTide:323 Study Steering Committee.

Semaglutide reduces risk of all-cause death

Semaglutide has been found to reduce the rates of all-cause death, including as a result of Covid-19, in those who are overweight or have obesity and established cardiovascular disease without diabetes.

FDA clears genetically engineered TIL therapy for solid tumour trials

Grit Biotechnology has received investigational new drug (IND) approval from the US Food and Drug Administration (FDA) for its genetically engineered tumour-infiltrating lymphocyte (TIL) product GT201.

Clinical trial investigates oral MRGPRX2 antagonist in urticaria

The first patient has been treated in a Phase II trial of EVO756 in adults with chronic inducible urticaria (CIndU).

Is this drug the answer to cannabis addiction?

Brain disease specialist Aelis Farma has announced results from the clinical Phase IIB trial study of AEF0117, evaluating its efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD).